Gene therapy for sickle cell disease may help improve a major contributing factor to stroke risk in patients, reports a new ...

The findings were published today in the American Journal of Hematology. Improving blood flow in the brain with gene therapy A small but significant percentage of patients with sickle cell disease are ...

Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type ...

Patients who underwent stem cell transplants (SCTs) involving mismatched unrelated donors (MMUDs) had a 1-year overall ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety ...

Specifically, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program requirements from two BCMA-directed CAR T-cell therapies for multiple myeloma — ciltacabtagene autoleucel ...

Three major Mount Sinai research studies offer new hope for patients facing chronic lymphocytic leukemia (CLL), a rare type of blood cancer. The ...

June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic that aims to regulate iron homeostasis ...

A new study shows that patients achieve good outcomes with a partial match drawn from the national public registry of donors ...